Highest-materiality recent filing
Processa's binding term sheet with Intact Therapeutics for PCS12852 expires without deal
Binding Term Sheet dated June 17, 2025 with Intact Therapeutics expired February 12, 2026.
Processa shareholders approve 10x authorized share increase and reverse split
Shareholders approved increase in authorized common shares from 100M to 1B (13.7M for, 3.0M against).
Processa shareholders approve 10x increase in authorized shares, reverse split up to 1:50
Approved increase of authorized common shares from 100M to 1B (13.7M for, 3.0M against).
On July 25, 2025, Processa filed a prospectus supplement to its Form S-3 (Registration No. 333-279588) for an equity distribution agreement with A.G.P./Alliance Global Partners.
Terminated licensing agreement with Ocuphire Pharma (now Opus Genetics) for PCS3117, returning rights to original licensor.
Processa prices $7M public offering of common stock and warrants at $0.25/unit
Gross proceeds of $7M before expenses; offering of 28M shares/pre-funded warrants plus 28M common warrants.
Near-term payments: $2.5M option exercise fee plus 3.5% equity stake in Intact upon closing.
Processa receives Nasdaq bid-price deficiency notice; 180 days to regain compliance
Nasdaq notified Processa that common stock bid price closed below $1.00 for 30 consecutive business days.
Processa closes $5M public offering; Series A/B warrants at $0.65 exercise price
Gross proceeds of $5.0M from offering closed Jan 29, 2025; net proceeds for general corporate purposes.
Processa provides pipeline update, Q2 net loss $3.0M; Phase 2 NGC-Cap trial underway
FDA cleared IND for NGC-Cap Phase 2 in July 2024; multicenter trial in metastatic breast cancer initiated, initial data expected mid-2025.
FDA clears IND for Processa's NGC-Cap Phase 2 trial in breast cancer
FDA cleared IND for NGC-Cap Phase 2 trial in advanced/metastatic breast cancer.
Processa appoints Russell Skibsted as CFO; James Stanker retires
Russell Skibsted appointed CFO effective July 16, 2024; succeeds James Stanker who retired.
Processa presents NGC-Cap Phase 1b data at AACR; poster modified
David Young, President R&D, presented two abstracts at AACR 2024 on NGC-Cap and Project Optimus.
On April 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement.
by mutual agreement, James Stanker resigned as Chief Financial Officer of the Company, effective July 15, 2024.
announced the appointment of Mr. Russell Skibsted, Effective July 16, 2024 as its Chief Financial Officer.
Max materiality 0.80 · Median 0.55 · Most common event other_material